• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIOTRONIK AG, BUELACH, SWITZERLAND ORSIRO (US) 3.5/13; CORONARY DRUG-ELUTING STENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIOTRONIK AG, BUELACH, SWITZERLAND ORSIRO (US) 3.5/13; CORONARY DRUG-ELUTING STENT Back to Search Results
Model Number 401739
Medical Device Problem Codes Failure to Advance (2524); Device Dislodged or Dislocated (2923)
Health Effect - Clinical Code No Clinical Signs, Symptoms or Conditions (4582)
Date of Event 05/10/2021
Type of Reportable Event Malfunction
Additional Manufacturer Narrative
Combination product: yes.
 
Event or Problem Description
An orsiro drug-eluting stent system was selected for treatment of a severely calcified lesion (90 percent stenosis degree) in the mildly tortuous ostial cx.The device could not pass the heavily calcified lesion even with the use of a guideliner (teleflex 6f).During attempt to remove the device, the stent dislodged.The stent could not be snared and was adapted to the vessel wall with another stent.It was stated that the stent might got caught in a previous implanted stent.
 
Additional Manufacturer Narrative
Combination product: yes neither the complaint instrument nor the angiographic material was returned for analysis.Therefore, no technical investigation on the subject could be performed.The production documentation was reviewed to establish whether a deviation from the manufacturing process could be the cause for the reported event.Review of the production documentation confirmed that the instrument was manufactured according to specifications and passed all in-process and final inspections.As a part of final inspection every stent system undergoes visual inspection to ensure correct embedding and homogeneous crimping of the stent.Further, the stent outer diameter is verified to 100 percent and the stent retention force of a defined amount of samples is tested from every lot.Based on the conducted investigations, no manufacturing or material related root cause could be determined.Considering the physicians event description, the root cause for the complaint event is most likely related to the patients anatomy (i.E.Previously implanted stent).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ORSIRO (US) 3.5/13
Common Device Name
CORONARY DRUG-ELUTING STENT
Manufacturer (Section D)
BIOTRONIK AG, BUELACH, SWITZERLAND
ackerstrasse 6
buelach CH-81 80
CH  CH-8180
MDR Report Key11917291
Report Number1028232-2021-03020
Device Sequence Number17065397
Product Code NIQ
UDI-Device Identifier07640130438941
UDI-Public07640130438941
Combination Product (Y/N)Y
Initial Reporter CountryUS
PMA/510(K) Number
P170030
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2021
Reporter Type Manufacturer
Initial Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup
Report Date (Section B) 05/13/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Expiration Date11/13/2021
Device Model Number401739
Device Catalogue NumberSEE MODEL NO.
Device Lot Number10196063
Was Device Available for Evaluation? No
Initial Date Received by Manufacturer 05/13/2021
Supplement Date Received by Manufacturer06/22/2021
Initial Report FDA Received Date06/01/2021
Supplement Report FDA Received Date06/23/2021
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Patient Sequence Number1
Outcome Attributed to Adverse Event Hospitalization;
Patient Age68 YR
-
-